Archive: 04/09/2017

Low incidence of adverse events for A-fib catheter ablation

(HealthDay)—The incidence of adverse events (AEs) is low for patients undergoing catheter ablation (CA) for atrial fibrillation (AF), according to a study published online Aug. 30 in JACC: Clinical Electrophysiology.

Sep 4, 2017

0

0

Liraglutide tied to reduced progression of diabetic kidney disease

(HealthDay)—For patients with type 2 diabetes and high cardiovascular risk receiving usual care, the addition of liraglutide is associated with lower rates of development and progression of diabetic kidney disease, according ...

Sep 4, 2017

0

0

Coronary artery calcium may be best indicator of CVD risk

(HealthDay)—The cardiovascular event rate is low for patients with no coronary artery calcium (CAC), which improves overall prediction among patients thought to be at risk of atherosclerotic cardiovascular disease (ASCVD), ...

Sep 4, 2017

0

1

Millions who buy health insurance brace for sharp increases

Millions of people who buy individual health insurance policies and get no financial help from the Affordable Care Act are bracing for another year of double-digit premium increases, and their frustration is boiling over.

Sep 4, 2017

0

0

Electronic alert doesn't up appropriate thromboprophylaxis

(HealthDay)—A computer-based alert system with a Geneva Risk Score calculation tool in the electronic patient chart does not improve appropriate thromboprophylaxis in patients admitted to general medical wards, according ...

Sep 4, 2017

0

0

Take the back pain out of backpacks

(HealthDay)—Backpacks can mean backaches for schoolchildren, but an orthopedic surgeon has advice for parents and kids about how to keep soreness at bay.

Sep 4, 2017

0

6

Novartis eyes chief executive shake-up in 2018

Swiss pharmaceutical giant Novartis said Monday its chief executive for the past seven years, Joseph Jimenez, will step down in 2018, allowing chief medical officer Vasant Narasimhan to take the reins.

Sep 4, 2017

ICON8 trial reaffirms standard dosing in ovarian cancer chemo

European women with ovarian cancer can safely stick to the standard three-week dosing schedule for paclitaxel rather than boosting up to a weekly dose-dense regimen, according to results of the phase III ICON8 trial to be ...

Sep 4, 2017